Arlene H. Sharpe, MD, PhD - American Association for.

SITC is proud to welcome Elizabeth M. Jaffee, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Helen E. Heslop, MD, of Baylor College of Medicine, Lieping Chen, MD, PhD, of Yale School of Medicine, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute and Arlene Sharpe, MD, PhD, of Harvard Medical School as the keynote speakers for the 35 th Anniversary Annual Meeting.

Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the discovery of the PD-L1 pathway and the importance of the pathway in inhibiting anti-tumor immunity. Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better. Sharpe adds that the pathway was initially.

Arlene Sharpe. Harvard Medical School. Dr. Sharpe received her A.B. from Harvard University, where she did undergraduate thesis research in the laboratory of Dr. Jack Strominger. She received her M.D. and Ph.D. degrees from Harvard Medical School where she did PhD thesis research on reovirus pathogenesis in the laboratory of Dr. Bernard Fields. She completed residency training in Pathology at.

Arlene Sharpe, MD, PhD, Harvard Medical School George Fabyan Professor of Comparative Pathology; Chair, Department of Immunology. Clifford J. Tabin, PhD, Harvard Medical School George Jacob and Jacqueline Hazel Leder Professor of Genetics; Chair, Department of Genetics. How to apply How to donate. ABOUT. History; Management; Board of Trustees; Scientific Advisory Board; Italian Scholarship.

An Answer to Cancer? Using the immune system to fight cancer -- Longwood Seminar. from Harvard Medical School Business. 3 years ago. Oncologists are turning to a novel form of therapy to combat cancer: retraining or reengineering the immune system to quash tumor growth. In this seminar, hear from Harvard Medical School scientists and clinicians on the latest approaches that use the body’s.

Arlene Sharpe, MD, PhD George Fabyan Professor of Comparative Pathology, Interim Co-Chair, Microbiology and Immunobiology, Co-Director, Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, USA The major interest of the Sharpe laboratory is to study functions of T cell costimulatory pathways and their immunoregulatory roles in controlling the balance between T cell.

Arlene Sharpe, MD, PhD Harvard Medical School Past Members Spyros Artavanis-Tsakonas, PhD Yale University School of Medicine Joseph Avruch, MD Massachusetts General Hospital David Baltimore, PhD California Institute of Technology Cori Bargmann, PhD University of California, San Francisco Edward J. Benz Jr., MD Dana-Farber Cancer Institute Joan S. Brugge, PhD Harvard Medical School Donald Ganem.

Arlene Sharpe, MD, PhD, Harvard Medical School, Boston, Massachusetts Francoise Barre-Sinoussi is elected as a Foreign Associate to the National Academy of Medicine (Oct. 15, 2018) James P. Allison and Tasuku Honjo win The Nobel Prize in Physiology or Medicine (Oct. 1, 2018).

Harvard University and Merck are launching a collaboration that will provide significant research funding for up to four years to support immuno-oncology research led by Arlene Sharpe, MD, PhD, at Harvard Medical School (HMS). Sharpe, the George Fabyan Professor of Comparative Pathology and chair of the HMS Department of Immunology, will collaborate with researchers at Merck on a major project.

Dr. David serves as Innovation Strategist at the BRI, in addition to being Founder and Managing Director of Pharmagellan, a Boston-area biotech consulting firm. After studying molecular biophysics and biochemistry at Yale, Dr. David received his M.D. and Ph.D. degrees from Columbia University’s College of Physicians and Surgeons. Dr. David completed his clinical training in anatomic.

John Luckey, MD, PhD Department of Pathology. Steve Mentzer, MD Department of Surgery. Francisco J. Quintana, PhD Department of Neurology. Eric Rubin, MD, PhD Department of Medicine. Robert Rubin, MD Department of Medicine. Mohamed Sayegh, MD Department of Medicine. Arlene Sharpe, MD, PhD Department of Pathology. Frederick J. Schoen, MD.

The Society for Immunotherapy of Cancer (SITC) is pleased to announce Lieping Chen, MD, PhD, from Yale Cancer Center, Gordon Freeman, PhD, from the Dana-Farber Cancer Institute, and Arlene Sharpe.